Arbutus Biopharma Corporation
General ticker "ABUS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $676.3M (TTM average)
Arbutus Biopharma Corporation follows the US Stock Market performance with the rate: 57.6%.
Estimated limits based on current volatility of 2.5%: low 4.20$, high 4.42$
Factors to consider:
- Total employees count: 15 as of 2010
- Top business risk factors: Inability to raise capital, Third-party risks, Early stage company risks, Operational and conduct risks, Labor/talent shortage/retention
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [2.37$, 5.12$]
- 2025-12-31 to 2026-12-31 estimated range: [2.13$, 4.72$]
Financial Metrics affecting the ABUS estimates:
- Positive: with PPE of -8.4 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -10.90 <= 0.33
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: Interest expense per share per price, % of 0.02 <= 0.79
- Positive: Investing cash flow per share per price, % of 3.86 > -0.66
Short-term ABUS quotes
Long-term ABUS plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $39.02MM | $18.14MM | $6.17MM |
| Operating Expenses | $104.47MM | $96.24MM | $82.49MM |
| Operating Income | $-65.46MM | $-78.10MM | $-76.32MM |
| Non-Operating Income | $0.44MM | $5.25MM | $6.40MM |
| Interest Expense | $1.73MM | $0.46MM | $0.14MM |
| R&D Expense | $84.41MM | $73.70MM | $54.04MM |
| Income(Loss) | $-65.01MM | $-72.85MM | $-69.92MM |
| Taxes | $4.44MM | $0.00MM | $0.00MM |
| Profit(Loss)* | $-69.46MM | $-72.85MM | $-69.92MM |
| Stockholders Equity | $136.85MM | $106.02MM | $97.37MM |
| Assets | $195.42MM | $144.40MM | $131.71MM |
| Operating Cash Flow | $-35.36MM | $-85.94MM | $-64.85MM |
| Capital expenditure | $0.51MM | $1.01MM | $0.18MM |
| Investing Cash Flow | $-74.94MM | $50.77MM | $22.95MM |
| Financing Cash Flow | $31.81MM | $30.65MM | $52.00MM |
| Earnings Per Share** | $-0.46 | $-0.44 | $-0.38 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.